Recurrent Metastatic Nasopharingeal Carcinoma clinical trials

Explore recruiting recurrent metastatic nasopharingeal carcinoma clinical trials.

Also recruiting in Europe

Recurrent Metastatic Nasopharingeal Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Recurrent Metastatic Nasopharingeal Carcinoma trials by city

Recurrent Metastatic Nasopharingeal Carcinoma in Toronto Recurrent Metastatic Nasopharingeal Carcinoma in Vancouver Recurrent Metastatic Nasopharingeal Carcinoma in Montreal Recurrent Metastatic Nasopharingeal Carcinoma in Calgary Recurrent Metastatic Nasopharingeal Carcinoma in Edmonton Recurrent Metastatic Nasopharingeal Carcinoma in Ottawa Recurrent Metastatic Nasopharingeal Carcinoma in Winnipeg Recurrent Metastatic Nasopharingeal Carcinoma in Quebec City Recurrent Metastatic Nasopharingeal Carcinoma in Hamilton Recurrent Metastatic Nasopharingeal Carcinoma in Kitchener Recurrent Metastatic Nasopharingeal Carcinoma in London Recurrent Metastatic Nasopharingeal Carcinoma in Halifax Recurrent Metastatic Nasopharingeal Carcinoma in New York Recurrent Metastatic Nasopharingeal Carcinoma in Los Angeles Recurrent Metastatic Nasopharingeal Carcinoma in Chicago Recurrent Metastatic Nasopharingeal Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease